These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 20601278)
21. Cardiovascular effects of insulin sensitizers in diabetes. Jawa A; Fonseca V Curr Opin Investig Drugs; 2006 Sep; 7(9):806-14. PubMed ID: 17002258 [TBL] [Abstract][Full Text] [Related]
22. Advances in Antidiabetic Drugs Targeting Insulin Secretion. Ding Y; Li Y; Chen Q; Niu B Curr Pharm Des; 2018; 24(34):3990-3997. PubMed ID: 30417774 [TBL] [Abstract][Full Text] [Related]
23. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. Heald M; Cawthorne MA Handb Exp Pharmacol; 2011; (203):35-51. PubMed ID: 21484566 [TBL] [Abstract][Full Text] [Related]
24. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]. Ozawa H; Murai Y; Ozawa T Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054 [TBL] [Abstract][Full Text] [Related]
25. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors. Fang F; Kang Z; Wong C Mol Nutr Food Res; 2010 Mar; 54(3):345-52. PubMed ID: 19866471 [TBL] [Abstract][Full Text] [Related]
26. [Changes of the carbohydrate metabolism during combined surgical treatment in patients with diabetes mellitus complicated by necrotic-inflammatory foot injury]. Fedorenko AV Klin Khir; 2002; (11-12):68-9. PubMed ID: 12549301 [No Abstract] [Full Text] [Related]
27. Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1,25-dihydroxyvitamin D3 in diabetic rats. Lee TI; Kao YH; Chen YC; Tsai WC; Chung CC; Chen YJ Int J Cardiol; 2014 Sep; 176(1):151-7. PubMed ID: 25062566 [TBL] [Abstract][Full Text] [Related]
28. [Hypoglycemic activity of hypolipidemic preparations]. Titov VN Klin Med (Mosk); 2014; 92(5):18-28. PubMed ID: 25782302 [TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. Lee TI; Kao YH; Chen YC; Huang JH; Hsiao FC; Chen YJ Diabetes Res Clin Pract; 2013 Jun; 100(3):330-9. PubMed ID: 23369225 [TBL] [Abstract][Full Text] [Related]
30. Chemically chaperoning the actions of insulin. Hansen PA; Waheed A; Corbett JA Trends Endocrinol Metab; 2007; 18(1):1-3. PubMed ID: 17116401 [TBL] [Abstract][Full Text] [Related]
31. Targeting the unfolded protein response for disease intervention. Rivas A; Vidal RL; Hetz C Expert Opin Ther Targets; 2015; 19(9):1203-18. PubMed ID: 26166159 [TBL] [Abstract][Full Text] [Related]
35. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? Ahmed W; Ziouzenkova O; Brown J; Devchand P; Francis S; Kadakia M; Kanda T; Orasanu G; Sharlach M; Zandbergen F; Plutzky J J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586 [TBL] [Abstract][Full Text] [Related]
36. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors. Yumuk VD Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746 [TBL] [Abstract][Full Text] [Related]